Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Non-Current Deffered Revenue (2016 - 2018)

Corbus Pharmaceuticals Holdings has reported Non-Current Deffered Revenue over the past 4 years, most recently at $422337.0 for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue fell 57.32% year-over-year to $422337.0; the TTM value through Dec 2018 reached $422337.0, down 57.32%, while the annual FY2018 figure was $422337.0, 57.32% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $422337.0 at Corbus Pharmaceuticals Holdings, up from $392846.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $1.4 million in Q2 2018 and troughed at $58206.0 in Q2 2017.
  • A 4-year average of $480735.8 and a median of $338470.0 in 2015 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: tumbled 74.75% in 2016 and later surged 2224.34% in 2018.
  • Year by year, Non-Current Deffered Revenue stood at $260260.0 in 2015, then tumbled by 74.75% to $65724.0 in 2016, then surged by 1405.61% to $989550.0 in 2017, then crashed by 57.32% to $422337.0 in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for CRBP at $422337.0 in Q4 2018, $392846.0 in Q3 2018, and $1.4 million in Q2 2018.